Arcutis Biotherapeutics Files 8-K

Ticker: ARQT · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1787306

Arcutis Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyArcutis Biotherapeutics, Inc. (ARQT)
Form Type8-K
Filed DateJun 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, filing, financials

Related Tickers: ARQT

TL;DR

Arcutis filed an 8-K on June 17th covering votes, other events, and financials from June 12th.

AI Summary

Arcutis Biotherapeutics, Inc. filed an 8-K on June 17, 2025, reporting on events that occurred on June 12, 2025. The filing indicates that the company submitted matters to a vote of its security holders and also reported other events. Additionally, it included financial statements and exhibits.

Why It Matters

This 8-K filing signals important corporate actions and disclosures from Arcutis Biotherapeutics, potentially affecting investor decisions.

Risk Assessment

Risk Level: low — This filing is a standard corporate disclosure and does not appear to contain immediate negative news.

Key Numbers

  • 001-39186 — SEC File Number (Identifies the company's filing history)
  • 81-2974255 — IRS Employer Identification Number (Tax identification for the company)

Key Players & Entities

  • Arcutis Biotherapeutics, Inc. (company) — Registrant
  • June 12, 2025 (date) — Earliest event reported
  • June 17, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361 (address) — Principal executive offices

FAQ

What specific matters were submitted to a vote of Arcutis Biotherapeutics' security holders?

The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt.

What were the 'Other Events' reported by Arcutis Biotherapeutics on June 12, 2025?

The excerpt states that 'Other Events' were reported, but does not specify what those events were.

When was Arcutis Biotherapeutics, Inc. incorporated?

The company was incorporated in Delaware.

What is the principal executive office address for Arcutis Biotherapeutics, Inc.?

The principal executive offices are located at 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.

What is the SEC file number for Arcutis Biotherapeutics, Inc.?

The SEC file number is 001-39186.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Arcutis Biotherapeutics, Inc. (ARQT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.